Bone metabolic marker concentrations across the menstrual cycle and phases of combined oral contraceptive use.

[1]  D. Siscovick,et al.  Biochemical markers of bone turnover and risk of incident hip fracture in older women: the Cardiovascular Health Study , 2019, Osteoporosis International.

[2]  Simon B. Cooper,et al.  Bone metabolic responses to low energy availability achieved by diet or exercise in active eumenorrheic women. , 2018, Bone.

[3]  Yann Boissière.  JACOB: , 2017, The Biblical Hero.

[4]  R. Eastell,et al.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability , 2017, Osteoporosis International.

[5]  I. Fatouros,et al.  Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study , 2016, Endocrine.

[6]  Jian-Min Yuan,et al.  Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population. , 2016, Bone.

[7]  P. Luppa,et al.  Non-reproductive Effects of Anovulation , 2015, Geburtshilfe und Frauenheilkunde.

[8]  D. Clayton,et al.  Examining the role of oral contraceptive users as an experimental and/or control group in athletic performance studies. , 2013, Contraception.

[9]  L. Salmaso,et al.  Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle , 2013, Journal of Bone and Mineral Metabolism.

[10]  L. Hocking,et al.  Bone remodelling at a glance , 2011, Journal of Cell Science.

[11]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[12]  R. Kasch,et al.  Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations. , 2009, Experimental and clinical endocrinology.

[13]  Y. Onoe,et al.  Variations in Circulating Osteoprotegerin and Soluble RANKL during Diurnal and Menstrual Cycles in Young Women , 2009, Hormone Research in Paediatrics.

[14]  Michael Wagener,et al.  Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  R. Kagan,et al.  Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women , 2008, Menopause.

[16]  C. Nappi,et al.  Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. , 2008, Contraception.

[17]  A. Spiekerman,et al.  Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. , 2006, Contraception.

[18]  M. Guida,et al.  Effects of an Oral Contraceptive Containing Drospirenone on Bone Turnover and Bone Mineral Density , 2005, Obstetrics and gynecology.

[19]  M. Secic,et al.  Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. , 2004, Journal of pediatric and adolescent gynecology.

[20]  A. Paoletti,et al.  Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. , 2004, Contraception.

[21]  D. Felsenberg,et al.  A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. , 2004, Contraception.

[22]  G. Benagiano,et al.  Clinical profile of contraceptive progestins , 2004, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[23]  A. Di Spiezio Sardo,et al.  Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. , 2003, Contraception.

[24]  M. Heer,et al.  Changes in bone turnover in patients with anorexia nervosa during eleven weeks of inpatient dietary treatment. , 2002, Clinical chemistry.

[25]  G. Krassas,et al.  Oestrogen action on bone cells. , 2001, Journal of musculoskeletal & neuronal interactions.

[26]  J. Foidart,et al.  A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[27]  M. Hammar,et al.  Collagen metabolism markers as a reflection of bone and soft tissue turnover during the menstrual cycle and oral contraceptive use. , 2000, Contraception.

[28]  S. Prifti,et al.  Induction of estrogen receptor-α and -β activities by synthetic progestins , 2000 .

[29]  B. Fauser,et al.  Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. , 1999, Contraception.

[30]  P. Bacchetti,et al.  Changes in Bone Resorption During the Menstrual Cycle , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  A. Duncan,et al.  Effect of the Menstrual Cycle on Creatinine Clearance in Normally Cycling Women , 1998, Obstetrics and gynecology.

[32]  C. Rosen,et al.  The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  K. Svärdsudd,et al.  Serum relaxin, symphyseal pain, and back pain during pregnancy. , 1996, American journal of obstetrics and gynecology.

[34]  P. Delmas,et al.  Decreased bone turnover in oral contraceptive users. , 1995, Bone.

[35]  W. Kuhnz,et al.  Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. , 1992, Contraception.

[36]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[37]  R. Karlsson,et al.  Oral contraception affects osteocalcin serum profiles in young women , 1992, Osteoporosis International.

[38]  U. Sohnius,et al.  Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users. , 1990, Contraception.

[39]  L. Mosekilde,et al.  Changes in biochemical markers of osteoblastic activity during the menstrual cycle. , 1990, The Journal of clinical endocrinology and metabolism.

[40]  J. Davison,et al.  SERIAL CHANGES IN 24 HOUR CREATININE CLEARANCE DURING NORMAL MENSTRUAL CYCLES AND THE FIRST TRIMESTER OF PREGNANCY , 1981, British journal of obstetrics and gynaecology.

[41]  H. Melzer,et al.  Influence of oral contraceptive agents on kidney function and protein metabolism , 2005, European Journal of Clinical Pharmacology.

[42]  A. LaCroix,et al.  Effects of contraceptive use on bone biochemical markers in young women. , 2001, The Journal of clinical endocrinology and metabolism.

[43]  P. Stehle,et al.  Oral Contraceptives Moderately Effect Bone Resorption Markers and Serum-Soluble Interleukin-6 Receptor Concentrations , 2001, Calcified Tissue International.

[44]  茶木 修.  The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women , 2001 .

[45]  S. Prifti,et al.  Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. , 2000, Gynecological Endocrinology.

[46]  D. Back,et al.  Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. , 1991, Hormone Research.

[47]  L. Dibbelt,et al.  Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. , 1991, Contraception.